Rain Oncology, Inc. (NASDAQ: RAIN)

This lawsuit is for anyone who acquired securities in Rain Oncology, Inc. (NASDAQ: RAIN) from July 20, 2021 through May 19, 2023.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by knowing but failing to timely inform investors that the Company’s anti-tumor drug, milademetan, was not effective.

On May 22, 2023, Rain announced the Phase 3 trial results of its antitumor drug, milademetan, revealing that the trial “did not meet its primary endpoint of progression free survival,” that “the results did not closely mirror prior clinical results” and that the Company would “re-evaluate the path forward for milademetan.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Rain Oncology, Inc. (NASDAQ: RAIN) from July 20, 2021 through May 19, 2023 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.